Garden Grove, Calif. (PRWEB) May 30, 2014
Idrasil, a 25mg tablet, is the first all-natural, standardized and consistent pill that is derived 100% from cannabis. Unlike other medical cannabis products, Idrasil is a pharmaceutical grade product that is reimbursable by many health insurance providers in California as well as Worker's Compensation. Unlike any other cannabis based product, such as those obtained through dispensaries, Idrasil is prescribed by a doctor based on a formulation of six milligrams for every 100lbs of weight per six hours avoiding any possible psychoactive effects and ensuring proper dosage.
While use and interest in cannabis for medical and therapeutic purposes has drastically increased throughout the nation with the recent passage of legislation legalizing use of marijuana in Colorado and Washington, patients across the nation are now clambering to get their hands on any medically based cannabis product regardless of their strength and efficacy. Recently, many reports of miraculous results in medical cannabis usage have pointed towards a low THC strain of marijuana oil known as “Charlotte's Web” for treating epilepsy. Lacking the formulary consistency of Idrasil, users of Charlotte's Web rely on trial and error between each batch of oil in hopes of delivering the right amount of cannabis to themselves or their loved ones.
“It is important for the medical community to understand that both tetrahydrocannabinol (THC) and cannabidiol (CBD) in equal parts are essential to the delivery of cannabis in order for it to be effective,” said Gregory A. Smith, MD, a spokesperson for Idrasil. “Whereas the CBD will act as more of an anti-inflammatory, the THC is the active component that binds to the brain's CB1 receptors where the anti-seizure effects to cannabis are derived.”
It is estimated that there are over 31,000,000 patients in the State of California alone whose medical conditions are treatable by Idrasil including acute or chronic pain, nausea, sleep disorder, anxiety, depression, ADHD, epilepsy, and multiple-sclerosis. Idrasil is currently offering 500,000 private shares at $10 per share to support its international marketing and distribution efforts.
C3 International, Inc. was formed to leverage first mover advantage and play a leadership role in the emergent cannabinoid therapeutics health sector. C3 is the developer of Patent(s)-pending Idrasil™, a breakthrough in pharmaceutical grade, medical cannabis, provided in a standardized and consistent, 25mg tablet. Idrasil™, delivered in a tablet form, is manufactured to help alleviate collateral suffering resulting from many different or overlapping serious medical conditions and the side effects of conventional treatments, like chemo-therapies.
C3 PATIENTS ASSOCIATION – 855-437-2745